Gene therapy shot could end monthly eye injections for wet AMD
NCT ID NCT06825858
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 24 times
Summary
This early-stage trial tests a gene therapy called KH658 in 9 people with wet age-related macular degeneration (AMD). The treatment delivers a protein that blocks VEGF, the cause of abnormal blood vessel growth, using a harmless virus. The goal is to see if a single injection can safely reduce or replace the need for regular eye injections. Participants must be 50-85 and have previously responded to standard anti-VEGF therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kanghong Investigative Site
Phoenix, Arizona, 85016, United States
-
Kanghong Investigative Site
Lemont, Illinois, 60439, United States
-
Kanghong Investigative Site
Memphis, Tennessee, 38138, United States
Conditions
Explore the condition pages connected to this study.